OPKO Health, Inc. (OPK) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 149.37M USD | Liabilities, Current |
| Cash and equivalents | 300.76M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Available-for-sale Securities, Current |
| Customer receivables | 81.89M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 61.85M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $149.37M | $300.76M | (m) | $81.89M | $61.85M | (m) |
| 2026-03-31 | (m) | $148.38M | $331.86M | (m) | $79.64M | $64.40M | (m) |
| 2025-12-31 | (m) | $146.68M | $364.41M | (m) | $90.25M | $65.82M | (m) |
| 2025-09-30 | (m) | $169.32M | $411.97M | (m) | $94.58M | $64.95M | (m) |
| 2025-06-30 | (m) | $171.18M | $267.28M | (m) | $99.38M | $66.34M | (m) |
| 2025-03-31 | (m) | $295.85M | $428.83M | (m) | $96.15M | $64.00M | (m) |
| 2024-12-31 | (m) | $193.10M | $426.58M | (m) | $118.02M | $56.80M | (m) |
| 2024-09-30 | (m) | $211.66M | $400.08M | (m) | $106.58M | $59.41M | (m) |
| 2024-06-30 | (m) | $219.55M | $40.58M | (m) | $105.31M | $60.15M | (m) |
| 2024-03-31 | (m) | $204.34M | $75.64M | (m) | $111.37M | $59.37M | (m) |
| 2023-12-31 | (m) | $200.05M | $95.88M | (m) | $123.38M | $65.70M | (m) |
| 2023-09-30 | (m) | $200.55M | $138.62M | (m) | $117.45M | $68.96M | (m) |
| 2023-06-30 | (m) | $226.45M | $108.11M | (m) | $210.98M | $73.75M | (m) |
| 2023-03-31 | (m) | $222.42M | $110.83M | (m) | $121.49M | $75.41M | (m) |
| 2022-12-31 | (m) | $213.48M | $153.19M | (m) | $127.31M | $74.06M | (m) |
| 2022-09-30 | (m) | $267.27M | $180.84M | (m) | $123.19M | $71.43M | (m) |
| 2022-06-30 | (m) | $215.47M | $210.46M | (m) | $158.43M | $83.31M | (m) |
| 2022-03-31 | (m) | $309.17M | $102.28M | (m) | $212.75M | $99.41M | (m) |
| 2021-12-31 | (m) | $330.01M | $134.71M | (m) | $259.64M | $86.50M | (m) |
| 2021-09-30 | (m) | $283.04M | $148.60M | (m) | $255.19M | $112.86M | (m) |
| 2021-06-30 | (m) | $303.98M | $65.76M | (m) | $265.86M | $134.72M | (m) |
| 2021-03-31 | (m) | $403.93M | $89.50M | (m) | $320.46M | $159.10M | (m) |
| 2020-12-31 | (m) | $375.48M | $72.21M | (m) | $286.31M | $132.34M | (m) |
| 2020-09-30 | (m) | $335.89M | $36.29M | (m) | $241.54M | $111.87M | (m) |
| 2020-06-30 | (m) | $279.54M | $21.61M | (m) | $214.35M | $72.97M | (m) |
| 2020-03-31 | (m) | $245.09M | $34.53M | (m) | $132.48M | $58.70M | (m) |
| 2019-12-31 | (m) | $249.12M | $85.45M | (m) | $134.62M | $53.43M | (m) |
| 2019-09-30 | (m) | $270.14M | $64.67M | (m) | $140.76M | $50.11M | (m) |
| 2019-06-30 | (m) | $283.37M | $111.11M | (m) | $148.29M | $48.29M | (m) |
| 2019-03-31 | (m) | $396.06M | $207.25M | (m) | $144.38M | $44.61M | (m) |
| 2018-12-31 | (m) | $288.32M | $96.47M | (m) | $143.91M | $42.30M | (m) |
| 2018-09-30 | (m) | $317.83M | $43.72M | (m) | $157.37M | $43.38M | (m) |
| 2018-06-30 | (m) | $306.86M | $80.38M | (m) | $152.78M | $46.75M | (m) |
| 2018-03-31 | (m) | $318.08M | $99.94M | (m) | $158.64M | $49.81M | (m) |
| 2017-12-31 | (m) | $301.33M | $91.50M | (m) | $165.52M | $49.33M | (m) |
| 2017-09-30 | (m) | $258.95M | $100.36M | (m) | $233.92M | $46.95M | (m) |
| 2017-06-30 | (m) | $283.05M | $130.53M | (m) | $251.75M | $48.29M | (m) |
| 2017-03-31 | (m) | $264.95M | $131.05M | (m) | $238.89M | $47.49M | (m) |
| 2016-12-31 | (m) | $263.30M | $168.73M | (m) | $220.28M | $47.23M | (m) |
| 2016-09-30 | (m) | $254.51M | $144.65M | (m) | $223.83M | $43.19M | (m) |
| 2016-06-30 | $385.02M | $281.24M | $156.01M | $15.63M | $213.37M | $42.05M | 1.37× |
| 2016-03-31 | (m) | $267.23M | $174.97M | (m) | $204.48M | $40.58M | (m) |
| 2015-12-31 | (m) | $251.90M | $193.60M | (m) | $193.88M | $39.68M | (m) |
| 2015-09-30 | (m) | $357.59M | $212.14M | (m) | $189.72M | $40.69M | (m) |
| 2015-06-30 | (m) | $180.48M | $221.22M | (m) | $26.98M | $20.52M | (m) |
| 2015-03-31 | (m) | $182.84M | $348.19M | (m) | $19.06M | $18.32M | (m) |
| 2014-12-31 | (m) | $83.11M | $96.91M | (m) | $19.97M | $16.60M | (m) |
| 2014-09-30 | (m) | $76.84M | $118.26M | (m) | $21.21M | $16.66M | (m) |
| 2014-06-30 | (m) | $79.40M | $134.01M | (m) | $23.11M | $18.33M | (m) |
| 2014-03-31 | (m) | $84.50M | $156.40M | (m) | $19.66M | $18.86M | (m) |
| 2013-12-31 | (m) | $91.85M | $185.80M | (m) | $19.77M | $18.08M | (m) |
| 2013-09-30 | $202.21M | $71.38M | $155.83M | $25.00M | $21.37M | $19.52M | 2.83× |
| 2013-06-30 | $191.31M | $59.47M | $119.06M | $50.03M | $22.23M | $19.78M | 3.22× |
| 2013-03-31 | $231.31M | $58.22M | $181.60M | $28.55M | $21.17M | $23.02M | 3.97× |
| 2012-12-31 | $60.14M | $52.38M | $27.36M | $11.62M | $21.16M | $22.26M | 1.15× |
| 2012-09-30 | $61.49M | $46.44M | $23.43M | $18.92M | $19.14M | $21.49M | 1.32× |
| 2012-06-30 | $71.19M | $31.71M | $38.17M | $17.12M | $15.90M | $17.09M | 2.25× |
| 2012-03-31 | $78.36M | $29.70M | $47.12M | $15.00M | $16.25M | $18.39M | 2.64× |
| 2011-12-31 | (m) | $18.78M | $71.52M | (m) | $12.54M | $13.34M | (m) |
| 2011-09-30 | $100.11M | $20.24M | $47.23M | $40.18M | $12.69M | $10.52M | 4.95× |
| 2011-06-30 | $109.38M | $21.53M | $38.85M | $55.00M | $15.53M | $16.33M | 5.08× |
| 2011-03-31 | (m) | (m) | $47.88M | (m) | (m) | (m) | (m) |
| 2010-12-31 | $31.33M | $27.60M | $18.02M | $0.00 | $13.32M | $19.96M | 1.14× |
| 2010-09-30 | (m) | (m) | $15.18M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $9.69M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $42.66M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $6.68M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |